{"name":"Equillium","slug":"equillium","ticker":"EQ","exchange":"NASDAQ","domain":"equilliumbio.com","description":"Equillium is a biopharmaceutical company focused on developing treatments for immunology and autoimmune diseases. The company's pipeline includes Itolizumab (Bmab 600) in phase 1, EQ101 in phase 2, and BNZ-1, which was discontinued. Equillium is positioned to capitalize on the growing demand for immunology treatments.","hq":"La Jolla, CA","founded":0,"employees":"","ceo":"Bruce Steel","sector":"Immunology / Autoimmune","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$75M","metrics":{"revenue":41095000,"revenueGrowth":0,"grossMargin":0,"rdSpend":37039000,"netIncome":-22398000,"cash":31887000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Itolizumab (Bmab 600) patent cliff ($0.0B at risk)","drug":"Itolizumab (Bmab 600)","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Equillium Announces FDA Clearance of IND for EQ101","summary":"Equillium received FDA clearance to initiate a phase 2 clinical trial for EQ101.","drugName":"EQ101","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Equillium Reports Third Quarter 2023 Financial Results","summary":"Equillium reported its third quarter 2023 financial results, including revenue and net loss.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Equillium Enters into Collaboration Agreement with Bristol Myers Squibb","summary":"Equillium entered into a collaboration agreement with Bristol Myers Squibb to develop and commercialize Itolizumab (Bmab 600).","drugName":"Itolizumab (Bmab 600)","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQdjBiZW5PNWJfVThBdU5sZWdNaUFFVTc3eU1wNTdWa3ozWGZNMVB5RzdDMDl4My1NXzRNRk9BWUdLUlN1dkx3OGFOM1p2WVV0UG5DcTF2NkRaSnVwS0tLUXR3U0pkYVhIR2JyM2VvTWs4clppMHIyZWdQNnVWa3Y3ZU5jVmZZdVljdmd0VDU3RXNNRW1pRXV0c2RKLWtHVFE4TGc0RkJuZldOQkI3eDRvMEZ4RUM5ODB5VUVPMEJR?oc=5","date":"2026-04-02","type":"pipeline","source":"Stock Titan","summary":"New Equillium hire gets options for 32,000 shares at $2.04 - Stock Titan","headline":"New Equillium hire gets options for 32,000 shares at $2.04","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNYnV3VVZrUWM1OVRWZjhKLVl0M0tyYXdsZGVybEVZRDJWSmdla2R3dy1iU1dRWEVHaVhMVENiSF83SkdWUEdPWHhoczREX2FaWW11LTdXcFhrQmZ2WTlaQXUtX05KdE9fVnlnRDdWeGhReFl6bm9uV3VKekNBNy14R1RiWk81V0VWWkJRMmpONjZfUzk5Rm5WakZ1NDR3RHhaRVJpc3RlYWl5Z0EyWGc?oc=5","date":"2026-03-30","type":"pipeline","source":"Stock Titan","summary":"Reverse split range 1-for-2–1-for-20; Equillium (NASDAQ: EQ) seeks 400M cap - Stock Titan","headline":"Reverse split range 1-for-2–1-for-20; Equillium (NASDAQ: EQ) seeks 400M cap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOMzk2VXVuWFAtYlhSdF9lYWQycGpzM0xvcVB5WFhOLVdMNDlpLXZBbmVoYXRwWmt0R0xZcDlDdWcyYWVvMVdheUtKRTZyUFoyYl9fOGJvZTZjX1dwb0g2YmE5MmoyMHNwTVlaTkh6SGpuSDRBVEtKNHZjZnczaW8yUThtTFpRWVhiTVpQa2pLczJfRzRhUkE?oc=5","date":"2026-03-26","type":"pipeline","source":"Stock Titan","summary":"[EFFECT] Equillium, Inc. SEC Filing - Stock Titan","headline":"[EFFECT] Equillium, Inc. SEC Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNSlZwa0FsenljSUNEeVNIMWtGNDV5Q2htbnBaczNHaG5BTy00ZVhNWm9fUWNPTkxiM2RoYzF2MGNpaVJwdkU2d0pVaklaUTZWUTN1T3dpbDhRa2VTdDhhSUp4dng5ZXJfdGM4SXhVbVZMam9MMU5xZm9oRnpFUk9nbUx3RG9NUTJNZ0JaT2trelUzTjBMREtaSlpvNGN2OVJIOWc?oc=5","date":"2026-03-25","type":"pipeline","source":"Stock Titan","summary":"Equillium (EQ) shifts to EQ504 focus, raises $85M and funds into 2029 - Stock Titan","headline":"Equillium (EQ) shifts to EQ504 focus, raises $85M and funds into 2029","sentiment":"neutral"},{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNX1AwNmR3SFZjd2dlY2NDdFA0ZEkybEI5T2Q5MUd5Ym9kVHJiSHphcW9wOW9GeUVLNFpMbU50cmdGWjEtWTljbThJYU9rVFByTU0tU2ZwZXlpLXNiTU1fRjY3TEhLWU9kcVJJNFBNdXo1bWNDS3Y1dHJNOExuelVfTTdsYWdMTGluWXBDbEJGWDlNWTZZdGVmZjlVT2xZcm5TUjhR?oc=5","date":"2026-03-18","type":"pipeline","source":"Stock Titan","summary":"Biotech Equillium set for Roth fireside chat, investor talks - Stock Titan","headline":"Biotech Equillium set for Roth fireside chat, investor talks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOOFZDNkNuYXp6LUlsSUxRWUh1WXZ5eTJwd2p3Q0xrbXVZTTFvQUltQjZrbGVROXZHanhnd0lMN1QtRmR3UnR5LWdMdWU2NGhKOHlSUDZPSDdlTXVXT1FocmkwejgweGREVkpPTF9RMVdPenlEVVA1bjlteGtfRk1IS25ISmp1Z2NTTURDZElNV3BoY0JxQWlWRlF6bnNlWUZZcU92TXFVb18?oc=5","date":"2026-03-16","type":"pipeline","source":"Stock Titan","summary":"Equillium (EQ) COO exercises options and sells 120,312 shares under plan - Stock Titan","headline":"Equillium (EQ) COO exercises options and sells 120,312 shares under plan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOYnU4MWotOTdWSUpBTFJUbTdzYzRhbnhJblBWWlpacGEyV2tKbnozRGVvbXZNVlZsX05odDNrOWQ4dmloa3RSemp5ZTNxOHhqeDhmbHMzRUFtOVcyZWEzYVlOVmhDYVpxd21nWkpKa2Y2RjVNZWtOTVU0eENOd3d0TlBSWTc3WWpma2NCaGd2Q3pXaVp0WGRCcnhibzhvSHBuREJNT2d4TEctcXRiYUE?oc=5","date":"2026-03-13","type":"pipeline","source":"Stock Titan","summary":"Experimental colitis pill gets $35M boost, funded into 2029 - Stock Titan","headline":"Experimental colitis pill gets $35M boost, funded into 2029","sentiment":"neutral"},{"date":"2026-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNallCbWpnRV9kbVh5cTFZWGh6Qll5MTFJc2V3SHZGRG51R2k4VWtjU21aM2tfTkdMbXZ5eWRtZ1kxZ2hVbU5fWTFGVDBpMmd3bnMwNmRIdks2d1o3NjNuVTJFQ2daQkNxWkJKbHFkRk5Md1hBa3BQNkt5cmN1OHhzMmI0UDUtRnNmdkRLaWx6ay1CZFlHb1NDejZyOFZWTldvZG8zR24taXNvUHRqYnc?oc=5","date":"2026-02-25","type":"pipeline","source":"Seeking Alpha","summary":"Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC (NASDAQ:EQ) - Seeking Alpha","headline":"Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC (NASDAQ:EQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNNFEtMEptd3gyUmR5N2dYeFVKSnlvaXZraUlqOGM0RW9paFFjRFRuRmhOQ3BQSUVsQzkwaWVwNEVZaGFUTUFNOWFuOEMyaDRiR043ZENQcmxMZmw3ZmV4a1Zqd25tQUF1UVpoNzJSREYtVXFYYlVYbTFIaWFHYTJaN3Z1bHZtbHVteGFSdDAtcFVqUWdNZng1a01DNF9UZkY0anV1OW9ra3I2SkdjYU9ud2paRHpJeDF1dnRqdnlhWnlYZWJqQTgwTk4xMDBPbG9Ib3FpZTVKQU3SAd4BQVVfeXFMUGxuMXQ4YjVIdVpNY0otbWVCWG44RHZJcDJfVHE1YThGSjUzcGh4MXhwV1oyV2dmdVlhTU5uOXZFTmFiQk9UeExBbm1jdWRRN1YwTy1wRlNhdXk0YThqOEM1RlJPZzQzX1BJY0lTY3JERVNoS04xaWFQVWhGYW9DanJmSUdZbmY3LWg5Vl9MY3NkOU9EYkZwc1g5dTBxbkxDZExDYXJIamZhTVZOTTdxYWg5MmFsa1dpRFR3RVFpZXZJdDRZOXdhUGlWekF5WTEyelplRl9jaFY4ZzVwdWRB?oc=5","date":"2025-11-10","type":"pipeline","source":"simplywall.st","summary":"Investors Don't See Light At End Of Equillium, Inc.'s (NASDAQ:EQ) Tunnel - simplywall.st","headline":"Investors Don't See Light At End Of Equillium, Inc.'s (NASDAQ:EQ) Tunnel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQTmZ5bUhDUlVvSjZKb2RiZFRRWWREcVZ4QkhyTGwzaF9QQ2dlMnZmaHVvTWJKOVdPM2xaUmF5SGlIWTNjY29Sd0V2aWRhTVJ6RjNORHhZX183djZQOUs2ZGF5TDZYbnp1bHpkOXJ2b1BKTEFFZkM0SkxRcExibWU3YmlBQkVQa0xvcHNKVmZhRkpOSlhQMmRJNWtVSFdKbU5VSXJhQ19JbjM2ODRMVm1jLWtHeTU5SENQSFpvZzBzM0pCbFBIMEpnYW5YX3BseWxqcUVxdXNZWmfSAd4BQVVfeXFMUHkzVkNPYWxMSjhBRjJlMEZSTnhJeHVaTUstUUJENF9BQkVDUG9RS2hJYmtvWHJPRVVMRHNQOFpBNE9GQjMybXUwWEw3SDU0Rl9EUFJ2ak01WXdnaVY3NTh0MDdEVlNxLU5ZczhIdWVOOFJzLXRsVXMyWGtndDZtTjlfR1VoT1dZVnl3c2dCNHd6ZG5YQzNDb1hvYW4wc2lvNDhNNHJXNXR5VmFXTW1sSVZya201YjhlVXhuZ2c4NjJwcGJhU2VabENsVEE1NThSNGpiaHZkcnRLYktvOEl3?oc=5","date":"2025-08-04","type":"pipeline","source":"simplywall.st","summary":"Spotlight On 3 Promising Penny Stocks With Over $20M Market Cap - simplywall.st","headline":"Spotlight On 3 Promising Penny Stocks With Over $20M Market Cap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBmRnN3Mi1zVmdwZVVDTDg1ZFl5R0FjWnpYbG1FUEllZU9zeHdyXzc1c0kyb3VyczZlMnY5My1BUTM1Q3Buazk4UFV6RlFQSzZQ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"EQ Stock Price, News & Analysis - Stock Titan","headline":"EQ Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPaEVGZlpPemtsODlZX3ROUzVVREE2UklYWHpoSUk5WVFFak9SVUY1UEpjU2czZUxCczNJc3dhNjd3Z0NYWEJVSEtwMXJFMHl6dzMwV2VGaUllLTBPS1AzbzhRelh5YUdOX1JlemhpQjl4NFA3NlViWWJoY2dDbUYxSDM1SDUxTVVEOThpX0hnMTUwOUxVeFI3Yw?oc=5","date":"2022-12-06","type":"deal","source":"The Pharma Letter","summary":"Ono Pharma buys rights to Equillium’s itolizumab - The Pharma Letter","headline":"Ono Pharma buys rights to Equillium’s itolizumab","sentiment":"neutral"}],"patents":[{"drugName":"Itolizumab (Bmab 600)","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Gilead Sciences","Regeneron Pharmaceuticals"],"therapeuticFocus":["Immunology","Autoimmune Diseases"],"financials":{"source":"sec_edgar","revenue":41095000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":41095000,"period":"2024-12-31"},{"value":41095000,"period":"2024-12-31"},{"value":36084000,"period":"2023-12-31"},{"value":36084000,"period":"2023-12-31"},{"value":15759000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":37039000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-22398000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":31887000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}